<DOC>
	<DOCNO>NCT00288522</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy safety 3 dos Somatuline Autogel 60mg control muscle infiltration edema , eyelid retraction extraocular muscular contraction patient active thyroid-associated ophthalmopathy moderate intensity .</brief_summary>
	<brief_title>Lanreotide ( Somatuline Autogel ) Thyroid-associated Ophthalmopathy Treatment</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Graves Ophthalmopathy</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<criteria>Patients autoimmune thyroid disease whose centre 's medical record confirm presence euthyroidism least two month include study Thyroidassociated ophthalmopathy diagnose minimum six month his/her participation study , well document centre 's medical record base moderate intensity thyroidassociated ophthalmopathy bad eye Patients whose ophthalmopathy activity demonstrate positive octreoscan The patient present compressive optical neuropathy sign require immediate surgical treatment suffers serious intensity thyroid ophthalmopathy The patient treat radioiodine his/her thyroid disturbance past 6 month The patient 's thyroidassociated ophthalmopathy treat previously ( except drop local measure ) plan treat radioiodine thyroidectomy his/her autoimmune thyroid disease study suffers myopia , glaucoma eye disease could modify ophthalmological progress The patient smoker 5 cigarette per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>